Skip to main content
. 2011 Jan;4(1):3–14. doi: 10.1177/1756285610391693

Figure 2.

Figure 2.

Kaplan–Meier analysis of time conversion to secondary progressive multiple sclerosis (SPMS) in patients in the highest (MIN) and lowest (MAX) quartiles of (a) cumulative dose of subcutaneous (sc) interferon (IFN) beta-1a and (b) cumulative time on sc IFN beta-1a.